Labiotech's 15 biopharma companies to watch in 2026
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
-
Gesprochen von:
-
Von:
Über diesen Titel
Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech players that they thought would be the ones to watch in 2026. Now you can read that article at Labiotech-dot-EU, and we’ve linked it in the show notes here in your podcast player, too, but on today’s episode I’m joined by Jules, Roohi, and Willow who explain a little more about the companies that caught their eye and what might be expected of those companies in the year ahead.
15 companies, three journalists, all in one special podcast as we uncover the companies to watch in 2026.
1:18 Meet Jules Adam
2:30 Abivax
4:04 AAVantgarde Bio
6:10 Isotope Technologies Munich (ITM)
8:16 MaaT Pharma
9:55 Novo Nordisk
13:15 Meet Willow Shah-Neville
14:29 Kardigan
18:23 Braveheart Bio
21:16 Beam Therapeutics
24:34 MindMed
27:39 Kailera Therapeutics
32:36 Meet Roohi Peter
33:30 Aspen Neuroscience
34:45 Reunion Neuroscience
36:14 MapLight Therapeutiucs
37:41 Hope Medicine
38:59 Regenxbio
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
- Keep an eye on these 15 biotech companies in 2026
- Biotech in 2025: A retrospective
- Eight of the biggest immunology and inflammation (I&I) deals in 2025
